In this episode, Scott Becker outlines the top five not-for-profit health systems in the U.S. ranked by annual revenue.
The Latest
This episode features Rommy Foteh, President and COO of Neuromonitoring Associates, and Seth Pfaltzgraff, Healthcare Client Director at Macedon Technologies. They discuss the operational impact of the No Surprises Act and how technology and strategic automation are helping providers streamline…
Nearly 8 in 10 U.S. adults in a recent Harvard/SSRS poll said parents should be required to have children vaccinated against preventable diseases like measles, mumps and rubella to attend school — including most Democrats and Republicans. And about 7…
The Make America Healthy Again Commission, a newly created advisory body under HHS, published a report on chronic disease and children’s health Sept. 9. The commission’s “Make Our Children Healthy Again Strategy” covers a slew of topics, including environmental chemicals,…
A study found that GLP-1 drugs are associated with a lower risk of fractures, including hip and osteoporotic fractures. The research, led by scientists from China and published in Acta Diabetologica, analyzed more than 490,000 adverse event reports from the…
The White House has asked Congress to extend government funding until Jan. 31, a four-month delay that would keep agencies running at current levels past the Sept. 30 expiration, Politico reported Sept. 9. The request was part of a wish…
In this episode, Scott Becker highlights five healthcare companies hit hard over the past year.
New Orleans-based Ochsner Health has built a 70-person “sales team for tech” that helps with all things Epic and clinicians can’t do without, the health system’s CIO told Becker’s. The 47-hospital system launched its Epic Academy in 2012 — it…
The average tenure of healthcare CEOs is slightly shorter than the average across industries, according to a recent report from executive search firm Crist Kolder Associates. Healthcare CEOs serve an average tenure of 7.3 years, compared to 7.5 years across…
Novartis is acquiring biopharmaceutical company Tourmaline Bio for $1.4 billion to boost its cardiovascular pipeline. Tourmaline develops pacibekitug, a drug used to treat atherosclerotic cardiovascular disease, according to a Sept. 9 news release from Novartis. Novartis said the drug is…